Literature DB >> 3935667

Absence of gamma interferon and interleukin 2 production during active visceral leishmaniasis.

E M Carvalho, R Badaró, S G Reed, T C Jones, W D Johnson.   

Abstract

The lymphocytes from eight patients with active visceral leishmaniasis (VL), a disease associated with marked immunologic dysfunction, were examined for ability to produce interleukin 2 (IL-2) and gamma interferon during in vitro cultivation. It was found that both IL-2 and gamma interferon production, in response to leishmania antigen, was absent during the active disease, but was restored after successful chemotherapy. Untreated VL patients produced IL-2 and gamma interferon when stimulated with phytohemagglutinin (PHA). Six patients with either active cutaneous or mucosal leishmaniasis, a disease not associated with immunosuppression, showed high levels of gamma interferon in response to leishmania antigen and PHA. Since IL-2 and gamma interferon have been shown to have important roles in the immune response and in the killing of leishmania, their absence may represent a key defect in the immune response in VL.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3935667      PMCID: PMC424308          DOI: 10.1172/JCI112209

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  23 in total

1.  Immunity in kala-azar.

Authors:  P E MANSON-BAHR
Journal:  Trans R Soc Trop Med Hyg       Date:  1961-11       Impact factor: 2.184

2.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

3.  T cell growth factor: parameters of production and a quantitative microassay for activity.

Authors:  S Gillis; M M Ferm; W Ou; K A Smith
Journal:  J Immunol       Date:  1978-06       Impact factor: 5.422

4.  Separation of functional subsets of human T cells by a monoclonal antibody.

Authors:  E L Reinherz; P C Kung; G Goldstein; S F Schlossman
Journal:  Proc Natl Acad Sci U S A       Date:  1979-08       Impact factor: 11.205

Review 5.  Interleukin 2.

Authors:  K A Smith
Journal:  Annu Rev Immunol       Date:  1984       Impact factor: 28.527

6.  Impaired production of lymphokines and immune (gamma) interferon in the acquired immunodeficiency syndrome.

Authors:  H W Murray; B Y Rubin; H Masur; R B Roberts
Journal:  N Engl J Med       Date:  1984-04-05       Impact factor: 91.245

7.  Morphology of the spleen and lymph nodes in fatal visceral leishmaniasis.

Authors:  B Veress; A Omer; A A Satir; A M El Hassan
Journal:  Immunology       Date:  1977-11       Impact factor: 7.397

8.  Suppressed antibody responses to sheep erythrocytes in mice with chronic Trypanosoma cruzi infections are restored with interleukin 2.

Authors:  S G Reed; J A Inverso; S B Roters
Journal:  J Immunol       Date:  1984-12       Impact factor: 5.422

9.  Reversible defect in antigen-induced lymphokine and gamma-interferon generation in cutaneous leishmaniasis.

Authors:  H W Murray; B Y Rubin; S Carriero; A M Acosta
Journal:  J Immunol       Date:  1984-10       Impact factor: 5.422

10.  Defective gamma interferon production in leprosy. Reversal with antigen and interleukin 2.

Authors:  N Nogueira; G Kaplan; E Levy; E N Sarno; P Kushner; A Granelli-Piperno; L Vieira; V Colomer Gould; W Levis; R Steinman
Journal:  J Exp Med       Date:  1983-12-01       Impact factor: 14.307

View more
  110 in total

1.  KSAC, the first defined polyprotein vaccine candidate for visceral leishmaniasis.

Authors:  Yasuyuki Goto; Ajay Bhatia; Vanitha S Raman; Hong Liang; Raodoh Mohamath; Alessandro F Picone; Silvia E Z Vidal; Thomas S Vedvick; Randall F Howard; Steven G Reed
Journal:  Clin Vaccine Immunol       Date:  2011-06-01

Review 2.  Interferons 1992. How much of the promise has been realised?

Authors:  M A Volz; C H Kirkpatrick
Journal:  Drugs       Date:  1992-03       Impact factor: 9.546

3.  Histopathology of lymphoid organs in experimental leishmaniasis.

Authors:  C E Corbett; R A Paes; M D Laurenti; H F Andrade Júnior; M I Duarte
Journal:  Int J Exp Pathol       Date:  1992-08       Impact factor: 1.925

4.  In vitro responses to Leishmania antigens by lymphocytes from patients with leishmaniasis or Chagas' disease.

Authors:  S G Reed; E M Carvalho; C H Sherbert; D P Sampaio; D M Russo; O Bacelar; D L Pihl; J M Scott; A Barral; K H Grabstein
Journal:  J Clin Invest       Date:  1990-03       Impact factor: 14.808

5.  Th1/Th2 cytokine profile in patients coinfected with HIV and Leishmania in Brazil.

Authors:  Maria Zilma Andrade Rodrigues; Maria Fernanda Rios Grassi; Sanjay Mehta; Xing-Quan Zhang; Luana Leandro Gois; Robert T Schooley; Roberto Badaro
Journal:  Clin Vaccine Immunol       Date:  2011-08-10

6.  A novel Leishmania infantum recombinant antigen which elicits interleukin 10 production by peripheral blood mononuclear cells of patients with visceral leishmaniasis.

Authors:  I Suffia; B Ferrua; X Stien; B Mograbi; P Marty; D Rousseau; K Fragaki; J Kubar
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

7.  Elevation of serum B-cell activating factor levels during visceral leishmaniasis.

Authors:  Yasuyuki Goto; Satoko Omachi; Chizu Sanjoba; Yoshitsugu Matsumoto
Journal:  Am J Trop Med Hyg       Date:  2014-08-25       Impact factor: 2.345

8.  Granulocyte-macrophage colony-stimulating factor in combination with pentavalent antimony for the treatment of visceral Leishmaniasis.

Authors:  R Badaró; C Nascimento; J S Carvalho; F Badaró; D Russo; J L Ho; S G Reed; W D Johnson; T C Jones
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994       Impact factor: 3.267

9.  Novel 17-kilodalton Leishmania antigen revealed by immunochemical studies of a purified glycoprotein fraction recognized by murine T lymphocytes.

Authors:  M M Rodrigues; M T Xavier; L Mendonça-Previato; M A Barcinski
Journal:  Infect Immun       Date:  1988-07       Impact factor: 3.441

10.  Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: homology to Epstein-Barr virus open reading frame BCRFI.

Authors:  P Vieira; R de Waal-Malefyt; M N Dang; K E Johnson; R Kastelein; D F Fiorentino; J E deVries; M G Roncarolo; T R Mosmann; K W Moore
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.